IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack
IPS HEART is pleased to announce the addition to its Board, Dr. John Lynn Jefferies, Director Advanced Heart Failure and Cardiomyopathy Programs at the Cincinnati Children’s Hospital Medical Center. Dr. Jefferies has recently completed a Phase I study in Duchenne Cardiomyopathy. He joins other prestigious members including Dr. Philippe Menasche, Professor of Thoracic and Cardiovascular Surgery, University of Paris Descartes. Dr. Menasche is currently the world’s first and only clinician to have a Phase I cardiomyocyte stem cell clinical trial in Paris, which recently announced promising results and provides a proof of concept for work similar to IPS HEART.
About IPS HEART:
IPS HEART is a privately-held biopharmaceutical company dedicated to addressing heart attack, heart failure and duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells and heart disease. IPS HEART is a resident at Johnson & Johnson Innovation, JLABS at TMC in the Texas Medical Center. For more information, please visit www.ipsheart.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005262/en/
